Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Frank R. Ernst, Peri Barr, Riad Elmor & Schiffon L. Wong. (2017) Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study. Current Medical Research and Opinion 33:12, pages 2099-2106.
Read now
Read now
Danny Decoo & Mathieu Vokaer. (2015) Treatment adherence in multiple sclerosis: a survey of Belgian neurologists. Patient Preference and Adherence 9, pages 1669-1676.
Read now
Read now
Luis Lizán, Marta Comellas, Silvia Paz, José Luis Poveda, Dennis M Meletiche & Carlos Polanco. (2014) Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Preference and Adherence 8, pages 1653-1664.
Read now
Read now
Articles from other publishers (6)
Almudena Buesa-Estelléz, Roberto Cano-de-la-Cuerda, Rosa María Ortiz-Gutiérrez & Domingo Palacios-Ceña. (2019) The impact of pharmacological treatment on patients with multiple sclerosis. Disability and Health Journal 12:4, pages 615-621.
Crossref
Crossref
Maciej Wilski, Piotr Kocur, Mirosław Górny, Magdalena Koper, Anna Nadolska, Bartosz Chmielewski & Maciej Tomczak. (2019) Perception of Multiple Sclerosis Impact and Treatment Efficacy Beliefs: Mediating Effect of Patient's Illness and Self-Appraisals. Journal of Pain and Symptom Management 58:3, pages 437-444.
Crossref
Crossref
Gurpreet K Reen, Eli Silber & Dawn W Langdon. (2017) Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review. Journal of the Neurological Sciences 375, pages 107-122.
Crossref
Crossref
J Nicholas, JJ Ko, Y Park, P Navaratnam, HS Friedman, FR Ernst & V Herrera. (2017) Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing–remitting multiple sclerosis patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical 3:1, pages 205521731769611.
Crossref
Crossref
Barry Hendin, DeRen Huang, Sibyl Wray, Robert T Naismith, Sheri Rosenblatt, Javier Zambrano & Brian Werneburg. (2017) Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study. Neurodegenerative Disease Management 7:1, pages 39-47.
Crossref
Crossref
Tjalf Ziemssen, Pasquale Calabrese, Iris-Katharina Penner & Rainer Apfel. (2016) QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. Journal of Neurology 263:4, pages 784-791.
Crossref
Crossref